Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the multiple myeloma drug market will more than double from $2.1 billion in 2008 to $5.3 billion in 2018 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

The Pharmacor 2010 findings from the topic entitled Multiple Myeloma reveal that market growth will be driven by increased use of Celgene's Revlimid in the first-line setting and the launches of several premium-priced emerging therapies, most notably Celgene's pomalidomide and Onyx Pharmaceuticals' carfilzomib. Currently, the multiple myeloma market is dominated by Revlimid, Millennium Pharmaceuticals/Janssen-Cilag/Janssen's Velcade and Celgene/Fujimoto Seiyaku's Thalomid/Thaled.

"Carfilzomib and pomalidomide are the most promising emerging therapies in development, owing to their efficacy and tolerability," said Decision Resources Analyst Andrew Merron, Ph.D. "Carfilzomib and pomalidomide will compete with Velcade and Revlimid, respectively, although they will struggle to attain the same market share as these well-established agents."

The Pharmacor 2010 findings also reveal that, as the multiple myeloma market is becoming increasingly saturated with effective treatments, drug opportunities lie in the development of agents that improve survival and reduce toxicities compared with currently available therapies.

Through 2018, the launch of six emerging therapies will partially fulfill these unmet needs in treating multiple myeloma. In addition to pomalidomide and carfilzomib, the other emerging therapies that are forecast to launch through 2018 are Keryx Biopharmaceuticals/AEterna Zentaris's perifosine, Merck's Zolinza, Novartis's panobinostat and bendamustine (Cephalon's Treanda, Mundipharma's Ribomustin).

About Pharmacor 2010

The newly redesigned Pharmacor advisory service offers clients in the biopharmaceutical industry the most up-to-date information available on commercially significant disease topics.

About Decision Resources

Decision Resources ( is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at

All company, brand, or product names contained in this document may be trademarks or

  registered trademarks of their respective holders.      For more information, contact:   Decision Resources, Inc.   Christopher Comfort   781-296-2597 

First Call Analyst:
FCMN Contact:

SOURCE: Decision Resources

CONTACT: Christopher Comfort, Decision Resources, Inc., +1-781-296-2597,

Rheumatologists Are Eager to Use Roche-Genentech's ACTEMRA, According to New Study by BioTrends

View Now